Viking Therapeutics: Can Its Obesity Drug Pipeline Justify a Multi-Billion Dollar Valuation?

HC Wainwright maintains a $102 price target for Viking Therapeutics, citing strong cash reserves and key 2026 data readouts for obesity drug VK2735.

The investment firm HC Wainwright has reiterated its bullish stance on Viking Therapeutics, maintaining a "Buy" rating and setting a price target of $102 per share. With the stock currently trading around $32, this projection suggests a potential tripling of the share price. Analyst Joseph Pantginis bases this optimistic outlook on anticipated data readouts for the company's obesity treatment candidate, VK2735, expected in the third quarter of 2026.

Financial Health and Strategic Manufacturing

Viking Therapeutics enters this critical period from a position of financial strength. As of the end of 2025, the company reported a robust cash position of $706 million. Given a projected quarterly cash burn rate between $60 and $90 million, these reserves are deemed sufficient to fund ongoing Phase 3 clinical trials and prepare for potential regulatory submissions.

In preparation for a future commercial launch, the biopharma firm secured a comprehensive manufacturing agreement with CordenPharma in March 2025. The deal provides capacity for up to one billion tablets annually, alongside 100 million units for an injectable formulation, ensuring scalable production for both key delivery methods.

Upcoming Clinical Catalysts in Focus

Management has outlined a clear roadmap for 2026, with the third quarter emerging as a pivotal moment. A key event will be the results from a "waiting dose" study. This trial is designed to assess whether patients can successfully transition from weekly injections of VK2735 to either monthly injections or an oral dosage regimen, a factor critical for long-term patient convenience and adherence.

Also scheduled for Q3 2026 is the initiation of a Phase 3 study for the oral version of VK2735. This trial is strategically designed to leverage existing safety data from the subcutaneous (injection) program, potentially allowing it to proceed with 75% fewer patients. Such an approach would significantly reduce development costs and accelerate the timeline.

The clinical program continues to advance on other fronts. The VANQUISH-1 obesity study completed full patient enrollment by the end of 2025. Meanwhile, the VANQUISH-2 trial, which focuses on patients with both Type 2 diabetes and obesity, is nearing completion, though its primary endpoint data is not expected until 2027.

Insider Activity and Market Sentiment

Earlier this year, transactions by company executives drew attention. In early January, CEO Brian Lian sold 233,409 shares at an average price of $32.96, generating proceeds of approximately $7.69 million. This transaction reduced his direct holding by 8.54%. The company's CFO and COO executed similar sales during the same period. Notably, Lian retains a substantial stake of over 2.49 million shares.

Despite these insider sales, the broader analyst community remains decidedly positive. A consensus of 18 brokerage firms currently rates the stock as "Outperform," with an average price target of $93.59.

Trading approximately 24% below its 52-week high of $43.15, Viking's stock price reflects a period of consolidation. The data expected in the third quarter of 2026 will be a major test, determining whether the company's ambitious clinical strategy can support the high price targets set by Wall Street and pave its way toward a multi-billion dollar valuation.